Federated Hermes, Inc. Reneo Pharmaceuticals, Inc. Transaction History

Federated Hermes, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	SELL	$1.34 - $8.43 $79,668 - $501,197	-59,454 Reduced 98.92%	647 $1,000
Q3 2023 Nov 13, 2023	SELL	$5.44 - $8.13 $1,441 - $2,154	-265 Reduced 0.44%	60,101 $457,000
Q2 2023 Aug 14, 2023	SELL	$5.44 - $10.5 $98,050 - $189,252	-18,024 Reduced 22.99%	60,366 $396,000
Q1 2023 May 08, 2023	SELL	$2.44 - $6.42 $3,928 - $10,336	-1,610 Reduced 2.01%	78,390 $468,000
Q4 2022 Feb 13, 2023	BUY	$1.8 - $3.52 $90,000 - $176,000	50,000 Added 166.67%	80,000 $186,000
Q2 2022 Aug 15, 2022	BUY	$1.96 - $3.04 $25,480 - $39,520	13,000 Added 76.47%	30,000 $80,000
Q2 2021 Aug 16, 2021	BUY	$7.78 - $15.0 $132,260 - $255,000	17,000 New	17,000 $159,000

31M

50.8K

Ticker RPHM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,479,600
Market Cap $41.1M
Description
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.